NCT05368259Active, not recruitingNot Applicable
A Prospective, Open-Label, Multi-Center, Randomized, Pivotal Safety and Efficacy Study of the Allurion Gastric Balloon System + Moderate Intensity Lifestyle Modification Therapy Program vs. Moderate Intensity Lifestyle Modification Therapy Program for the Treatment of Adults With Obesity
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Allurion Technologies
- Enrollment
- 1,000
- Locations
- 34
- Primary Endpoint
- Responder Rate (RR) dichotomized at 5% TBWL at 48 week
Study Overview
Brief Summary
The objective for this clinical study is to provide FDA with clinical evidence regarding the effectiveness and safety of the AGBS + moderate intensity lifestyle modification therapy program, indwell time of the AGBS inside the stomach, and outcomes at 48 weeks.
Detailed Description
Prospective, open-label, multi-center, randomized study comparing the AGBS + moderate intensity lifestyle modification therapy program vs. moderate intensity lifestyle modification therapy program for the treatment of adults with obesity.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 22 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age ≥22 years and ≤ 65 years of age
- •BMI ≥30 kg/m2 and ≤ 40 kg/m2
- •Have signed study-specific Informed Consent Form
- •Willing to comply with study requirements, including follow-up visits
- •Documented negative pregnancy test in women of childbearing potential
- •Women of childbearing potential not intending to become pregnant for the duration of study participation. (Note: Women of childbearing potential must not be nursing at the time of treatment).
- •Fully ambulatory without any severe chronic orthopedic disease that requires reliance on crutches, walkers, or a wheelchair that could preclude exercise during the study
- •At least one unsuccessful attempt at weight loss, such as self-administered, commercial, or medically supervised lifestyle therapy program attempted within the 24 months preceding enrollment
Exclusion Criteria
- •Unable to walk 400 meters (the length of one loop of a track and field race track) without the use of an assistance device (e.g. cane, crutches, walker, wheel chair)
- •Symptomatic congestive heart failure, cardiac arrhythmia or unstable coronary artery disease
- •Pre-existing significant respiratory disease such as chronic obstructive pulmonary disease (COPD), severe sleep apnea and pneumonia
- •Previous bariatric surgery including adjustable gastric band and endoscopic sleeve gastroplasty, or likely to undergo bariatric surgery during the study period
- •Previous use of an intragastric gastric balloon
- •Current use of an intragastric device, PlenityTM and digital weight loss solutions (e.g. Noom or Calibrate)
- •History of any cancer other than non-melanoma skin cancer or papillary thyroid cancer within the last 5 years
- •Benign or malignant gastrointestinal tumors
- •History of chronic pancreatitis or acute pancreatitis within 12 months of enrollment
- •History of, or current, small bowel obstruction
- •History of severe GI motility disorder, such as severe gastroparesis
- •History of any esophageal, gastric, or small bowel surgery
- •History of, or current inflammatory bowel disease
- •Any history of intraperitoneal adhesions
- •Any history of open abdominal or gynecological surgery and/or radiation therapy to the abdomen, with the exception of cesarean sections performed at least 12 months prior to study enrollment
- •History of/or signs and symptoms of/or radiographic evidence of esophageal, gastric, or duodenal disease including, but not limited to hiatal hernia ≥5cm, inflammatory diseases, varices, severe gastroparesis, recent history of gastric or duodenal ulcers, stricture/stenosis, achalasia, severe GERD requiring maximal medical therapy, or LA Grade B, C, or D esophagitis
- •Diagnosis of autoimmune connective tissue disorder (e.g. lupus, erythematous, scleroderma)
- •Immunocompromised due to medications or medical disease or diagnosed with HIV
- •History of genetic or endocrine causes of obesity not adequately controlled by medication, including hypothyroidism
- •Type 1 diabetes or Type 2 diabetes with HgbA1c ≥ 7%, or treated with any anti-diabetic medications other than metformin
- •Significant acute and/or chronic infections
- •Severe coagulopathy defined as INR 1.5 or higher or platelet count <150, hepatic insufficiency, or cirrhosis
- •Unable or unwilling to discontinue use of aspirin and/or nonsteroidal anti-inflammatory agents (NSAIDs) at least 7 days prior to Allurion Deployment and continuing for 7 days after the Allurion Balloon is excreted
- •Currently taking the following medications (within 30 days prior to enrollment) and/or there is a need or anticipated need for these medications during the study: Excluded Medications Systemic corticosteroids Anticoagulant therapy (e.g., warfarin, dabigatran) or anti-platelet therapy Immunosuppressive therapy (e.g., azathioprine, cyclosporine) Narcotics, opiates, or benzodiazepines Insulin for treatment of diabetes Anti-seizure therapy (e.g., clonazepam, phenytoin) Anti-arrhythmics (e.g., amiodarone)
- •Inability or unwillingness to take anti-emetics during the device residence
- •Prescription or over-the- counter weight loss medication known to cause significant weight gain or weight loss within 90 days of study enrollment through study participation
- •Uncontrolled or severe psychiatric disease other than mild depression with a patient health questionnaire score of 9 or below
- •History of pulmonary embolism or deep venous thrombosis
- •Has cardiac pacemaker or other electric implantable device
- •Anemia defined as either:
- •Hgb <11 g/dL for females, <12 g/dL for males
- •Cessation of any nicotine product within 3 months of enrollment or plans to quit use during the study
- •Documented total body weight loss of ≥ 5% anytime 6 months preceding enrollment
- •Residing in a location without access to study site medical resources
- •History of or currently active eating disorders including night eating syndrome (NES), bulimia, or binge eating disorder
- •Unwilling to refrain from any reconstructive and/or cosmetic surgery that may affect body weight during the study such as mammoplasty and lipoplasty
- •Current, or history of, illicit drug use (defined per state law) or excessive alcohol use
- •Enrolled in another investigational study that has not completed the required primary endpoint follow-up period (Note: Subjects involved in a long-term surveillance phase of another study are eligible for enrollment in this study).
- •Current Use (within the last month) of any smoked or non-smoked marijuana products that contain THC or unwilling to abstain from THC containing marijuana products during the trial.
- •Any conditions that, in the opinion of each site investigator, may render the subject unable to complete the study with a likely final outcome, or lead to difficulties for subject compliance with study requirements, or could confound study data.
- •Subject is not of sufficient medical health as determined by the Investigator to participate in the study.
- •Employees/family members of Allurion Technologies or any of its affiliates or contractors
- •Immediate employees/family members of the Investigator, sub- Investigators, or their medical office or practice, or surgical, bariatric or hospital organizations at which study procedures may be performed
- •An immediate family member (by marriage or blood relationship) of another subject already enrolled in the study
- •Positive breath or stool test for H. Pylori
- •History of covid-19 with any residual symptoms
- •Known or suspected allergies to polyurethane
- •Uncontrolled high blood pressure defined as ≥160/100 mmHg with or without medications
- •Uncontrolled high cholesterol or triglycerides defined as LDL ≥190 mg/dL or triglycerides ≥500 mg/dL
- •Inability to swallow Allurion Practice Capsule
Outcomes
Primary Outcomes
Responder Rate (RR) dichotomized at 5% TBWL at 48 week
Time Frame: 48 weeks
Responder Rate (RR) dichotomized at 5% TBWL at 48 weeks is significantly greater than 50%
%TBWL is significantly greater than Control Group mean %TBWL at 48 weeks
Time Frame: 48 weeks
%TBWL is significantly greater than Control Group mean %TBWL at 48 weeks, with a super superiority margin of 3.0%
Secondary Outcomes
- Responder Rate (RR) dichotomized at both 5% and 10% TBWL at both 16 and 24 weeks(48 weeks)
Investigators
Study Sites (34)
Loading locations...
Similar Trials
Recruiting
Phase 2
The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular HemorrhageCommunicating HydrocephalusCerebral Intraventricular HemorrhageSecondary Normal Pressure HydrocephalusPost Hemorrhagic HydrocephalusNCT06563817Beijing Tiantan Hospital53
Terminated
Not Applicable
Early Treatment for Class II Division 1 Malocclusion With Twicare® and Herbst Removable AppliancesMalocclusion, Angle Class II, Division 1NCT02428621FCI System62
Unknown
Not Applicable
Firehawk™ Coronary Stent System in the Treatment of Coronary Chronic Total Occlusion Lesion(s)Drug-Eluting StentsPercutaneous Coronary InterventionTomography, Optical CoherenceNCT03040934Shanghai MicroPort Medical (Group) Co., Ltd.196
Suspended
Phase 4
TEM-PCR™ Prospective Clinical Utility StudyUpper Resp Tract InfectionNCT04248361Diatherix Laboratories, LLC314
Recruiting
Not Applicable
Comparison of 1 Month vs. 12 Months DAPT in Patients Undergoing PCI With Genoss® DESCoronary Artery DiseaseNCT05770674Kiyuk Chang2,186